Page 139 - Eceptor News Today

Researchers profiled cardiac tissue transcriptomes of COVID-19 patients.

A new study discovered immunoglobulins with powerful broad-acting neutralizing capacity against SARS-CoV-2 from SARS-CoV-2 convalescents.

Patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medications for heart failure had significantly lower blood potassium levels when taking patiromer—a drug that helps to prevent the body from absorbing too much potassium—compared with a placebo, in a study presented at the American College of Cardiology's 71st Annual Scientific Session.

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

Physicians prescribed significantly more guideline-directed medications for heart failure if they received a customized digital alert via an electronic health record (EHR) system when inputting medical orders shortly after seeing a patient, according to a study presented at the American College of Cardiology's 71st Annual Scientific Session.

In a recent study published in the journal Science, researchers observed differential effector functions of antibodies elicited by Pfizer’s BNT162b2 and Moderna’s messenger ribonucleic acid (mRNA)-1273 coronavirus disease 2019 (COVID-19) vaccines.

Researchers conducted selective phenotyping of coronavirus disease 2019 -relevant host proteins to facilitate target identification for drug repurposing.

Researchers discuss the evolution and mechanisms of mutations that have occurred in the spike protein of SARS-CoV-2.

Researchers discuss the development and structural characterization of therapeutic monoclonal antibodies targeting the surface glycoprotein of filoviruses.

Researchers determine mucosal SARS-CoV-2-specific antibody levels and their neutralizing effect in pediatric and adult patients.